1412 results about "Polysorbate 80" patented technology

A topical ophthalmic formulation in the form of an aqueous solution comprising a cyclosporin, hyaluronic acid or one of its salts, and polysorbate 80 is described.

A lyophilized solid composition of taxane (preferably docetaxel and paclitaxel), is suitable to prepare a pharmaceutical formulation to be administered to mammals, particularly humans, comprising a taxane, a tensoactive, a lyophilizing excipient, and acid; also essentially free from organic solvents. The solid composition is free from polysorbate 80 and polyoxyethylated castor oil; it is sterile; it is soluble in aqueous solutions in the absence of organic solvent and it has an apparent density from 0.05 g/ml to 0.45 g/ml. A procedure of double lyophilization obtains a solid composition of taxane. A pharmaceutical formulation of a taxane comprises a solid composition of lyophilized taxane and a solubilizing composition. A kit comprises the compositions and a syringe.

Disclosed is a topical skin care composition that includes water, silymarin, hydrolyzed algin, palmitoyl tripeptide 8, ceramide 2, pomegranate extract comprising pomegranate sterols, glycerin, disodium EDTA, caprylic/capric triglyceride, shea butter, C12-15 alcohols benzoate, dimethicone, glyceryl stearate and PEG 100 stearate, cetyl alcohol, stearyl alcohol, stearic acid, butylene glycol, caprylyl glycol, and (s) a mixture of acrylamide/sodium acryloyldimethyl taurate copolymer, isohexadecane, and polysorbate 80.

A method of characterizing a multi-component mixture for use in a bioprocess operation that includes providing a multi-component mixture standard with pre-determined amounts of known components; performing a Raman Spectroscopy analysis on the multi-component mixture standard; providing a multi-component test mixture from the bioprocess operation; performing a Raman Spectroscopy analysis on the multi-component test mixture; and comparing the analysis of the multi-component mixture standard and the multi-component test mixture to characterize the multi-component test mixture. In one embodiment, the multi-component mixture standard and the multi-component test mixture both comprise one or more of, at least two, at least three of, or each of, a polysaccharide (e.g. sucrose or mannitol), an amino acid (e.g., L-arginine, L-histidine or L-ornithine), a surfactant (e.g. polysorbate 80) and a pH buffer (e.g., a citrate formulation).

The present invention provides novel formulations which mitigate agitation-induced aggregation of immunogenic compositions particularly those having polysaccharide-protein conjugates. Specifically, the novel formulations comprise a poloxamer within a molecular weight range of 1100 to 17,400 which provides significant advantages over previously used surfactants including polysorbate 80. In one embodiment, the present invention provides a multivalent immunogenic composition having 15 distinct polysaccharide-protein conjugates and a poloxamer. Each conjugate consists of a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F or 33F) conjugated to a carrier protein, preferably CRM197.

A pharmaceutical formulation of taxane intended to be administered to mammals, preferably humans, comprises two compositions combined prior to being administered, forming a transparent solution free from precipitates, in which the compositions comprise a solid composition of lyophilized taxane, free from tensoactives, oils, polymers, solubility enhancers, preservatives and excipients; and a solubilizing composition of the lyophilized taxane solid composition that comprises at least one tensoactive. This formulation is free from polysorbate 80 and polyoxyethylated castor oil. A procedure is provided for the preparation of the solid composition by means of the lyophilization of taxane in a lyophilizing organic solvent. A kit for the injectable formulation of taxane comprises a prefilled syringe. Also a pharmaceutical taxane solution for perfusion, free from organic solvent, is provided.

The invention discloses an oxiracetam liposome injection which is characterized by comprising the following components in parts by weight: 1 part of oxiracetam, 3-18 parts of phospholipid, 1-12 parts of cholesterol, 0.5-7 parts of tween 80 and an appropriate amount of osmotic-pressure regulating agent and buffering solution. The oxiracetam liposome injection has the advantages of good stability, high entrapment rate, small toxic and side effects and simple preparation, and is suitable for clinical requirements.

The invention provides a composition of instant freeze-dried fibrinogen and thrombin preparation, a preparation method and a use thereof, and the composition comprises composition 1 composed of 35-70mg/ml of fibrinogen, 9-15mg/ml of sodium citrate, 7-12mg/ml of sodium chloride, 0.3-0.6mg/ml of polysorbate-80, 10-15mg/ml of mannitol, 4 -8mg/ml of arginine and 3.5-5.5mg/ml of glutamic acid by mg/ml and composition 2 composed of 700-1,200 mg/ml of thrombin, 3-6mg/ml of dextran 20, 15-25mg/ml of glycine, 5-7mg/ml of sodium chloride and 4-7mg/ml of calcium chloride by mg/ml. A sealant avoids the risk of spreading of AIDS virus, and the like, increases the drug stability, reduces the degeneration during the virus inactivation process by dry-heat method, protects biological activity, avoids local liquid storage of the using part caused by high permeability and the irritation of a large amount of inorganic salts to tissues, is conductive to the healing of trauma sites and ensures product safety and independent package to the maximum extent, thereby increasing storage time, facilitating use and meeting the clinical and field first-aid needs.

The invention discloses a racecadotril liposome solid preparation. The racecadotril liposome is prepared from racecadotril, soy lecithin, hydrogenated egg lecithin, cholesterol and tween 80 in the weight ratio of 1:2-8: 2-8:1.5-6:0.5-3; and the solid preparation is prepared from the racecadotril liposome and other pharmaceutically common auxiliary materials. The other pharmaceutically common auxiliary materials comprise filler, a disintegrating agent, a sweetener, an adhesive and a lubricant. The racecadotril liposome solid preparation improves the dissolubility of the racecadotril so as to improve bioavailability; a medicament is absorbed and distributed in a body fast; a curative effect is improved obviously; and the product quality of the preparation is improved and the toxic and side effects are reduced.

In one embodiment, the present invention provides a stable lyophilized formulation comprising an anti-EGFR antibody, preferably cetuximab; lactobionic acid; and a buffer, preferably histidine. In one preferred embodiment, the present invention provides a stable lyophilized formulation comprising about 50 mg/mL to about 140 mg/mL of ERBITUX?, about 0.125% lactobionic acid, about 25 mM histidine buffer at a pH of about 6.0, about 0.005% Tween 80, and about 1.875% glycine.

Lyophilizates containing docetaxel and the use thereof in preparing concentrated liquid formulations, and ready to use formulations for injection, as well as such concentrates and ready to use formulations themselves are disclosed in which Tween surfactants are avoided so that hypersensitivity reactions to Tween surfactants can be avoided and docetaxel can be administered at higher doses and/or for longer periods of time and/or for additional treatment cycles.

The invention discloses a preparation method of an organic and inorganic composite flushing liquid, and belongs to the technique of oil well cement well cementation. The flushing liquid comprises the following components: polysorbate-80, alkyl phenol polyethylene glycol ether, dodecyl benzene sulfonic acid sodium, sodium silicate, sodium pyrophosphate and water, wherein the mass ratio of each component is as follows: 20%-30% of polysorbate-80, 10%-15% of alkyl phenol polyethylene glycol ether, 5%-10% of dodecyl benzene sulfonic acid sodium, 10%-20% of sodium silicate, 5%-10% of sodium pyrophosphate and the balance of water. The flushing liquid is suitable for both the oil-based mud and water-based mud, has high flushing efficiency, improves the replacement efficiency of a well drilling liquid and cement sheath interfacial cementation quality, and can be used under the condition of 50 DEG C-200 DEG C.

The invention discloses a preparation method of high-purity 1,4-sorbitan, which is characterized by taking D-sorbitol as a raw material through dewatering twice and three times of crystallization. The method comprises the following steps of: (1) adding polyatomic alcohol in a reaction vessel; (2) stirring, heating and decompressing for removing free water; (3) cooling down and adding an acidic catalyst; (4) stirring, heating and decompressing for dehydrating a molecule of water; (5) neutralizing and filtering for separating the catalyst; (6) decolorizing; (7) carrying out crystallization for three times in lower alcohol to prepare the 1,4-sorbitan with more than 99% of content. The preparation method fills up the blank of 1,4-sorbitan industrial production technique; the prepared 1,4-sorbitan can be used for synthesizing high-purity surfactants, such as Span, Tween, sorbitan fatty acid ester or polysorbate and the like; and the polysorbate-80 synthesized by the prepared 1,4-sorbitan can satisfy the standard of injection-level pharmaceutic adjuvant.

The invention discloses an adipose mesenchymal stem cell cryoprotectant and a method for cryopreservation of adipose mesenchymal stem cells. The adipose mesenchymal stem cell cryoprotectant comprises, by weight parts, 80-88 parts of RPMI-1640 culture medium, 2-5 parts of FBS, 1-2 parts of sulfolane, 1.5-2.5 parts of 5 wt% of ethanol, 0.8-1.2 parts of 10 wt% of ethylene glycol, 0.8-1.2 parts of 10 wt% of 1,2-propylene glycol, 0.3-0.7 part of Tween 80, 0.5-1.5 parts of glycerin, 0.01-0.05 part of 50 U/mL of penicillin, 0.5-1 part of trehalose, 0.5-0.8 part of polyvinylpyrrolidone and 0.2-0.6 part of agar powder. The adipose mesenchymal stem cell cryoprotectant has the advantages of having no toxicity to the adipose mesenchymal stem cells and being good in cryopreservation effect.

The invention relates to a composition with the efficacies of whitening, moisturizing, repairing and caring the skin, as well as a preparation method and applications of the composition. The skin care composition is prepared from the following raw materials: water, sodium hyaluronate, sodium dihydrogen phosphate dihydrate, potassium chloride, sodium hydroxide, calcium chloride, glutamine, benzalkonium chloride, magnesium sulfate, aminobutyric acid, sodium ascorbate, alanine, arginine, lysine hydrochloride, valine, histidine, leucine, taurine, coenzyme A, alcohol, polysorbate 80, thiamine, disodium diphosphate, recombinant human epidermal cell growth factors and the like. The skin care composition disclosed by the invention can permeate the muscle bottom for replenishing water for the skin from the deep layer, so that the skin is full of elasticity, the color of the skin is brightened, the fine wrinkles are reduced, the skin is clean and watery, the balance of water and oil is regulated, the pores are shrunk, meanwhile, the brightness of the face can be increased, the injured epidermal layer is effectively repaired, the activity of tyrosinase is inhibited, the generation of skin melanin is reduced, so that the skin is healthy, natural and white.

The invention relates to the health care food processing technology field, and concretely relates to an extraction method for astragalus polysacharin. In the method, polysacharin is extracted by utilization of low temperature liquid nitrogen crushing, non-ionic surface active agent auxiliary and plant compound enzyme enzymolysis. The method is advantaged by easily available raw materials, simple technology, and convenient operation and is suitable for large-scale industrial production. On the one side, the method decreases extraction times, raises yield and purity of the polysacharin, and lowers the production cost, on the other side, the method maintains the stabilization of structures and properties of the polysacharin, and raises trophism, safety and acceptability of the astragalus polysacharin greatly. In addition, the added non-ionic surface active agent is preferably polysorbate-80, polysorbate-80 has promotion effects on cellulase and pectase in hydrolytic process, and has solubilizing effects on the polysacharin at the same time. The pretreatment time and the extraction time are shortened, the time cost is lowered, and economic benefits of enterprises are raised.

The invention provides cabazitaxel injection. The injection of each milliliter comprises the following components by weight: 10 to 100 milligrams of cabazitaxel, 250 to 800 milligrams of polysorbate 80, 200 to 600 milligrams of absolute ethanol, and 0.05 to 20 milligrams of citric acid. The cabazitaxel injection is a single preparation, does not need to be previously dissolved and prepared by using a special solvent, and can be directly diluted for administration; compared with the conventional preparation technology, the preparation has simple preparation process, low cost and good stability; meanwhile, the preparation shortens the time for preparing the medicinal liquor, improves the stability of clinical medicinal liquor, enhances the accuracy of administration dose, and reduces toxic or side reaction; and the preparation simplifies the preparation process of medicinal personnel, and reduces the risks of the preparation process on harm to the medicinal personnel and environmental pollution.

The invention discloses hydrochloric acid Fasudil liposome injection and new application thereof. The injection mainly comprises the following components according to parts by weight: 1 part of hydrochloric acid Fasudil, 2 to 20 parts of phospholipid, 0.5 to 10 parts of cholesterol and 1 to 8 parts of polysorbate 80. Simultaneously, the hydrochloric acid Fasudil liposome injection also can be used for treating vertebral artery type cervical spondylosis.

The invention provides a makeup-free face cream containing enriched emulsion and a preparation method of makeup-free face cream. The makeup-free face cream comprises, by weight percentage, 10.0-30.0% of enriched emulsion and 70.0-90.0% of liquid foundation, wherein the enriched emulsion comprises butanediol, polyglutamic acid, trehalose, sodium acrylate/acrylyl dimethyl sodium taurate polymer, isohexadecane, polysorbate-80, cyclopentyl siloxane (and) dimethiconol, moringa pterygosperma extracts and the like; the liquid foundation comprises physical skin whitening agent, colorant, cyclopentyl siloxane (and) trimethyl siloxy silicate ester, sorbitan sesquioleate, acrylic acid (ester)/C10-30 alkanol acrylic ester cross-linked polymer, magnesium aluminum silicate, xanthan gum, propylene glycol and the like. The makeup-free face cream is good in water and sweat resistance, natural in makeup feeling and easy to remove and has certain skin care effect.

The invention relates to a method for synthesizing high-purity polysorbate-80. The polysorbate-80 (I) is a partial esterified product of a sorbitan ethyoxyl compound and oleic acid. The method comprises the following steps of: (1) partially dehydrating sorbitol as a raw material under the action of an acid catalyst in a state of vacuum to obtain sorbitan (II); (2) carrying out addition polymerization on the sorbitan (II) and oxirane under the action of a base catalyst to obtain sorbitan polyethenoxy ether (III), wherein the addition number of the oxirane is 20; (3) reacting the sorbitan polyethenoxy ether (III) with the high-purity oleic acid under the action of an esterifying catalyst and refining to obtain the high-purity polysorbate-80. The invention leads the emulsifying and solubilizing performance of products to be more perfect and the quality of the products to easily meet the requirement of an injection class and has easily controlled quality and good stability; and the high-purity polysorbate-80 has lower blood dissolving rate in same concentration, and predictable and safer clinical use by being used as an auxiliary material for injection.

The invention discloses a pharmaceutical composition for improving the safety of Shenmai injection and a method for preparing the same. The pharmaceutical composition is a pharmaceutical composition for injection and is mainly prepared from red ginseng extract, dwarf lilyturf root extract and polyethylene glycol 12-hydroxy stearic acid ester. The pharmaceutical composition adopts a latent solvent with better safety and more obvious hydrotropy to replace the latent solvent polysorbate-80 which has potential safety hazard and influences the product quality, thus the reduction of the pH value of the Shenmai injection in the processes of storing and high temperature sterilization is obviously delayed, and the stability of the pharmaceutical composition is increased; besides, the safety of the polyethylene glycol 12-hydroxy stearic acid ester is higher than that of the polysorbate-80 and the dosage thereof is lower, thus the probability and the risk of untoward reactions of the pharmaceutical composition is reduced, and the safety for clinical application is improved.